0001104659-20-076542.txt : 20200624
0001104659-20-076542.hdr.sgml : 20200624
20200624194853
ACCESSION NUMBER: 0001104659-20-076542
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200617
FILED AS OF DATE: 20200624
DATE AS OF CHANGE: 20200624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KENNEDY WILLIAM JAMES
CENTRAL INDEX KEY: 0001448888
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 20986762
MAIL ADDRESS:
STREET 1: C/O XTL BIOPHARMACEUTICALS LTD
STREET 2: 711 EXECUTIVE BLVD., SUITE Q
CITY: VALLEY COTTAGE
STATE: NY
ZIP: 10989
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
4
1
tm2022959d1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-06-17
0
0001001316
TG THERAPEUTICS, INC.
TGTX
0001448888
KENNEDY WILLIAM JAMES
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK
NY
10014
1
0
0
0
COMMON STOCK
2020-06-17
4
S
0
7745
18.27
D
94633
D
COMMON STOCK
2020-06-22
4
A
0
15000
0
D
109633
D
In connection with the vesting of 15,000 shares on June 16, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Kennedy's tax obligations. Mr. Kennedy had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
Represents the weighted average sales price. The range of prices for such transaction was $18.20 to $18.36. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
Includes shares of restricted Common Stock, which vest over various time periods.
Reflects a grant of restricted shares that will vest on June 22, 2023.
/s/ William Kennedy
2020-06-24